Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded Randomized Study

Brief description of study

The purpose of this study is to understand if taking a malaria, autoimmunity, and arthritis medication called hydroxychloroquine can reduce the risk of becoming infected with the virus that causes COVID-19 or develop symptoms of COVID-19 after having contact with an infected person. Taking a medication to prevent becoming sick after exposure to an infected person is called “post-exposure prophylaxis” or “PEP.” The current standard of care is no treatment for people who had contact with a known or suspected case of COVID-19. Participants will be assigned by chance (chance is like flipping a coin) to either take hydroxychloroquine PEP or vitamin C for a total of 14 days of treatment which appears to be the approximate incubation period of SARS-CoV-2 infection.


Clinical Study Identifier: s20-00408
ClinicalTrials.gov Identifier: NCT04328961
Principal Investigator: Anna Bershteyn.


If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.